Celltrion Healthcare Reports Operating Profit of 36.2 Billion KRW Last Year, Up 337% Year-on-Year

Operating Profit Margin 22%... Record High Performance for 2 Consecutive Years

[Asia Economy Reporter Kim Ji-hee] Celltrion Healthcare announced on the 4th that it recorded consolidated sales of 1.6276 trillion KRW, operating profit of 362.1 billion KRW, and net profit of 240.4 billion KRW last year. Compared to the previous year, sales increased by 48%, operating profit and net profit rose by 337% and 270%, respectively. In particular, the operating profit margin was 22%, marking the highest performance for two consecutive years following 2019.

Celltrion Healthcare explained, "We achieved record-high performance thanks to price stabilization and steady prescriptions in the European market, expanded prescriptions of key pharmaceuticals in the United States, and increased sales in global regions such as Japan and Latin America."

It is especially analyzed that the expansion of prescriptions for 'Truxima' (generic name Rituximab) in the North American region contributed to Celltrion Healthcare's performance growth. Last month, Teva, Celltrion Healthcare's North American distribution partner, announced in its 2020 performance report that Truxima achieved a 24% market share in the United States as of the end of last year. This achievement within one year of launch is evaluated as a successful establishment in the U.S. market.

Celltrion Healthcare expects the growth trend to continue this year as well. First, the subcutaneous injection form of infliximab for autoimmune disease treatment, 'Remsima SC,' is set to expand in the European market. Remsima SC, newly launched in France last month, plans to complete launches in major European countries such as Spain, Italy, Belgium, Portugal, and Finland this month. In most European regions, direct sales of Remsima SC are expected to accelerate profit improvement.

Additionally, the high-concentration adalimumab biosimilar 'Yuflyma (CT-P17),' which received marketing authorization from the European Commission (EC) last month, is also expected to be fully reflected in Celltrion Healthcare's sales starting this year.

A Celltrion Healthcare official stated, "Despite the COVID-19 pandemic, our key pharmaceuticals continuously expanded prescriptions in the global market, resulting in record-high sales and operating profit," adding, "With major upcoming events such as expanding sales regions of existing products, launching new products, and global sales of COVID-19 therapeutics, we expect growth to continue this year as well."

This content was produced with the assistance of AI translation services.